ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Patients Pursuing Justice: Bard PowerPort Lawsuit Update

Lawsuit Legal News

Clearwater, Florida – In light of the growing number of patients experiencing severe complications from defective Bard PowerPort devices, Lawsuit Legal News (LLN) is committed to providing up-to-date information on the Bard PowerPort Lawsuit progress. As a leading legal news source, LLN aims to inform patients about litigation developments, court proceedings, and potential settlements regarding these critical medical devices.

Understanding the Bard PowerPort Lawsuit

Patients undergoing extensive medical treatments often require the implantation of a port catheter to facilitate routine blood draws, blood transfusions, and the administration of medications and intravenous fluids. Unfortunately, numerous patients who received fluids through defective port catheters manufactured by Bard Access Systems, a subsidiary of Becton, Dickinson, and Company, are now pursuing product liability lawsuits against the company.

A common theme among these lawsuits is the assertion that Bard PowerPort devices have critical design flaws, leading to deterioration or migration within the body. As a result, patients have suffered life-threatening injuries, including perforations of organs and blood vessels, due to these defective devices.

The pending lawsuits allege that Bard was aware of the risks associated with migration and infection, along with other severe injuries, yet failed to warn patients and the medical community adequately. Patients are seeking financial compensation for their damages, including medical expenses, lost wages, and pain and suffering.

Recent Updates in the Bard PowerPort MDL

As of April 2, 2024, the Bard PowerPort MDL continues to grow slowly, with 10 new cases joining the MDL in the past 30 days. While the number of potential plaintiffs remains relatively limited compared to other defective product mass tort cases, the ongoing litigation underscores the importance of holding Bard accountable for the harm caused by its defective devices.

Stay Informed with LLN

LLN is dedicated to keeping patients informed about the Bard PowerPort Lawsuit through regular updates on its website. With over 100 lawsuits involved in the Bard PowerPort Multidistrict Litigation (MDL), patients need to stay informed about the progress of the litigation and any developments that may impact their cases.

If you or a loved one has been affected by complications related to a Bard PowerPort device, it is crucial to begin the process of filing your claim as soon as possible.

Visit LawsuitLegalNews.com today to learn more about your options.

CASE INFORMATION
Judicial Panel on Multidistrict Litigation
BARD IMPLANTED PORT CATHETER PRODUCTS LIABILITY LITIGATION
MDL No. 3081



Lawsuit Legal News (LLN) is a trusted source of legal news and updates, providing comprehensive coverage of mass torts, multidistrict litigation (MDL), and other significant legal developments. Our mission is to empower individuals with the information they need to navigate the complexities of the legal system and pursue justice for their injuries and losses. For the latest updates on the Bard PowerPort Lawsuit and other important legal matters, visit our website and bookmark our dedicated Bard PowerPort Lawsuit page.

Lawsuit Legal News
800 N Belcher Rd., Clearwater, FL 33765
866-535-9515
https://lawsuitlegalnews.com/
Press Contact : Matt Dolman

Distributed by Law Firm Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.29
-3.81 (-1.53%)
AAPL  273.66
-1.59 (-0.58%)
AMD  261.77
+24.25 (10.21%)
BAC  54.59
+0.95 (1.78%)
GOOG  286.55
-5.19 (-1.78%)
META  610.41
-16.67 (-2.66%)
MSFT  504.51
-4.17 (-0.82%)
NVDA  192.26
-0.90 (-0.47%)
ORCL  229.40
-6.75 (-2.86%)
TSLA  430.26
-9.36 (-2.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.